MedWatch

Kåre Schultz after guidance hike: Hard to gauge generic competition

The US competitor to Lundbeck’s epilepsy drug Sabril is long in coming and this is partly the reason behind the new guidance hike for the Danish company. In the first half year of 2017, Sabril continued to gain market shares in the US.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us free for 14 days

Try a trial subscription for free access to our quality journalism

Frontpage right now

Lægemiddelstyrelsen er skuffet, men glad for bronzen

Lægemiddelstyrelsens direktør Thomas Senderovitz er skuffet over, at København ikke skal huse EMA, men også stolt over at have snuppet "bronzemedaljerne". Han påpeger dog også, at der ligger masser af arbejde forude i forbindelse med flytningen af lægemiddelagenturet.

Latest Top picks in English

Related articles